SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 66 filers reported holding SYROS PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $76,000 | -65.0% | 63,865 | -4.2% | 0.00% | – |
| Q4 2021 | $217,000 | -27.2% | 66,658 | -0.2% | 0.00% | – |
| Q3 2021 | $298,000 | -15.6% | 66,771 | +3.2% | 0.00% | – |
| Q2 2021 | $353,000 | +1.1% | 64,715 | +38.6% | 0.00% | – |
| Q1 2021 | $349,000 | -32.2% | 46,698 | -1.7% | 0.00% | -100.0% |
| Q4 2020 | $515,000 | +29.7% | 47,483 | +5.8% | 0.00% | 0.0% |
| Q3 2020 | $397,000 | -23.9% | 44,893 | -8.2% | 0.00% | 0.0% |
| Q2 2020 | $522,000 | +123.1% | 48,922 | +24.0% | 0.00% | – |
| Q1 2020 | $234,000 | -14.0% | 39,449 | +0.2% | 0.00% | – |
| Q4 2019 | $272,000 | -32.7% | 39,386 | +1.2% | 0.00% | -100.0% |
| Q3 2019 | $404,000 | +11.3% | 38,927 | -0.7% | 0.00% | 0.0% |
| Q2 2019 | $363,000 | +26.5% | 39,197 | +24.8% | 0.00% | 0.0% |
| Q1 2019 | $287,000 | +58.6% | 31,401 | -3.1% | 0.00% | – |
| Q4 2018 | $181,000 | -29.0% | 32,406 | +51.4% | 0.00% | – |
| Q3 2018 | $255,000 | +11.4% | 21,411 | -4.7% | 0.00% | – |
| Q2 2018 | $229,000 | +47.7% | 22,472 | +87.6% | 0.00% | – |
| Q1 2018 | $155,000 | +55.0% | 11,978 | +16.7% | 0.00% | – |
| Q4 2017 | $100,000 | -46.5% | 10,263 | -19.4% | 0.00% | – |
| Q3 2017 | $187,000 | -5.6% | 12,734 | +3.4% | 0.00% | – |
| Q2 2017 | $198,000 | – | 12,317 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 881,450 | $5,677,000 | 1.32% |
| IFP Advisors, Inc | 50 | $1,000 | 0.00% |
| Ten Capital Wealth Advisors, LLC | 219 | $1,000 | 0.00% |